Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Schering-Plough Now in the Feds' Crosshairs
- Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...
- Discussion threads 2008-07-10
- Is Merck Hanging Schering Out to Dry on Vytorin?
- Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Discussion threads 2008-07-07
- How Pharma Stacks the Deck with Medical Journals
- How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Discussion threads 2008-06-18
Additional Resources
- Schering's CEO, a Failed Trial and $16 Million
- Forbes' Matthew Herper and Michael Maiello have just jumped on a subject we alluded to -- perhaps too obliquely -- a few weeks back in discussing the eye-popping $30 million Schering-Plough CEO Fred Hassan pulled down in 2007. Not only did Schering post a $1.5 billion loss that year, it...
- Blog posts 2008-05-20
- Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial
- WHITEHOUSE STATION, N.J. & KENILWORTH, N.J. -- Merck and Schering-Plough said today that they strongly object to mischaracterizations about the ENHANCE (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) trial. "While the ENHANCE trial was time consuming and...
- Research articles 2008-01-25
- "Informant" Names Schering Execs Who Allegedly Knew Vytorin/Enhance Trial Was a Bust, Suit Claims
- An amended lawsuit filed over the Schering-Plough pension plan alleges that executives at the company suspected as early as 2005 that the Enhance Vytorin trial was a bust. Citing a "confidential informant," it also names names. by Jim Edwards
- Blog posts 2009-10-12
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- Merck, Schering Unable to Stop Digging in Vytorin Mess
- As an example of how not to handle a corporate crisis, it's hard to beat the growing scandal over Vytorin. That's the blockbuster anti-cholesterol drug whose clinical-trial data Merck and Schering-Plough sat on for a year or two after it showed that Vytorin was apparently no better than a...
- Blog posts 2008-04-14
- SOFTBANK joins forces with Motorola to launch 2.5GHz WiMAX mobility trial in Japan; Expertise gained from trial will enhance Motorola's MOTOwi4 portfolio of wireless broadband solutions.
- M2 PRESSWIRE-24 July 2006-MOTOROLA: SOFTBANK joins forces with Motorola to launch 2.5GHz WiMAX mobility trial in Japan; Expertise gained from trial will enhance Motorola's MOTOwi4 portfolio of wireless broadband solutionsC1994-2006 M2 COMMUNICATIONS LTD RDATE:24072006 TOKYO, Japan-- Motorola, Inc. (NYSE:MOT) today announced...
- Research articles 2006-07-24
- Schering-Plough Corp. Q4 2007 Earnings Call Transcript
- Question-and-Answer Session[Operator Instructions]. And your first question comes from Tim Anderson with Sanford Bernstein. Tim Anderson - Sanford Bernstein Couple of questions. On ENHANCE, can you just talk about, one data point that was in the January press release, which noted what the baseline IMT levels were which was...
- Earnings calls 2008-02-12
- Schering-Plough's Hassan Made Stock Gains as Price Tumbled and Layoffs Grew
- About 1,000 sales reps are being let go from Schering-Plough this week. That's on top of 60 animal health reps also being fired. Roughly 5,500 employees in general are being axed in Schering-Plough's cost-cutting drive. If you're one of those people, comfort yourself with the fact that...
- Blog posts 2008-09-19
- Windows 7 Volume License and Trial Availability
- Last month we made Windows 7 available to customers with Software Assurance and to MSDN and TechNet Subscribers. Today I am happy to announce two more ways for businesses to get Windows 7 for their deployment and evaluation. Volume License Availability, at a Discount ...
- News items 2009-09-01
- Cholesterol Drug Trials: A Victory for Abbott Means a Loss for Merck
- Derek Lowe submits: Over the weekend, the results in a small cardiovascular trial came out that compared Merck's MRK Zetia (ezetimibe/simvastatin) against Abbott's ABT Niaspan (time-release niacin). Niacin's an under-appreciated therapy in the field - it has tolerability problems, mainly irritating and uncomfortable hot flushing, but it really does...
- External links 2009-11-16
- ADVENTRX Receives FDA Clearance for CoFactor Phase III Pivotal Trial in Metastatic Colorectal Cancer
- SAN DIEGO -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that it has received clearance from the US Food and Drug Administration FDA under a Special Protocol Assessment SPA to initiate a Phase III pivotal clinical trial with CoFactor for the treatment of metastatic colorectal cancer. CoFactor is the Company's biomodulator...
- Research articles 2005-04-25
- OJ Simpson trial pushed back to September
- LAS VEGAS AFP — Disgraced former football star O.J. Simpson won't be tried on armed robbery and kidnapping charges until September, giving Simpson and two co-defendants six more months to prepare their cases. District Judge Jackie Glass on Friday said she didn't want to delay the trial but felt...
- Research articles 2008-03-07
- Network Solutions and Centraal Offer Free 60-Day Trial for RealNames Web Navigation Service
- HERNDON, Va.--BUSINESS WIRE--April 1, 1999--Network Solutions, Inc. (NASDAQ: NSOL) and Centraal Corporation today launched a 60-day free trial of the RealNamessm Web page addressing service. Centraal's RealNames service allows companies and individuals to subscribe easily remembered names and phrases for product or service Web pages. RealNames subscriptions complement domain...
- Research articles 1999-04-01
- Pro-Pharmaceuticals Engages WorldCare Clinical to Enhance and Accelerate the Phase II Trial
- NEWTON, Mass. -- WorldCare Clinical Provides Essential Independent Analysis & Interpretation of Patients' Images; Dr. Steven Nagel Named Phase ll Medical Monitor Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds that enable the targeted delivery of chemotherapy drugs to cancer cells, today announced it has engaged WorldCare...
- Research articles 2005-02-24
- ADVENTRX's Preliminary Results for CoFactor Phase II Trial Published at ASCO
- SAN DIEGO -- ADVENTRX Pharmaceuticals, Inc. (Amex:ANX) today announced that an abstract with preliminary safety and efficacy results from its Phase II trial using CoFactorTM with 5-fluorouracil (5-FU) for the treatment of metastatic colorectal cancer will be published in the American Society of Clinical Oncology ASCO 2005 Annual Meeting Proceedings....
- Research articles 2005-05-02
- Pro-Pharmaceuticals Retains PRA International for Clinical Trial In Cancer Patients
- Business Editors & Health/Medical Writers NEWTON, Mass.--BUSINESS WIRE--Dec. 19, 2002 Clinical Research Organization to Manage Current and Future Clinical Trials Pro-Pharmaceuticals Inc. (OTCBB:PROH), a developer of molecular techniques to enhance the delivery and effectiveness of proven anti-cancer drugs, today announced signing a master agreement with PRA...
- Research articles 2002-12-19
- << Previous
- page 1 of 1
- Next >>
